QS Investors’s Kyntra Bio KYNB Stock Holding History

QS Investors’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	$256K	Hold	384	–	–	﹤0.01%	991
2021 Q1	$334K	Buy	384 +4	+1%	+$4.26K	﹤0.01%	945
2020 Q4	$352K	Hold	380	–	–	﹤0.01%	928
2020 Q3	$391K	Sell	380 -1,100	-74%	-$1.18M	0.01%	815
2020 Q2	$1.5M	Sell	1,480 -4	-0.3%	-$3.71K	0.02%	596
2020 Q1	$1.29M	Hold	1,484	–	–	0.02%	588
2019 Q4	$1.63M	Sell	1,484 -20	-1%	-$20.4K	0.02%	643
2019 Q3	$1.39M	Hold	1,504	–	–	0.02%	681
2019 Q2	$1.7M	Sell	1,504 -24	-2%	-$26.3K	0.02%	641
2019 Q1	$2.08M	Sell	1,528 -8	-0.5%	-$10.8K	0.02%	595
2018 Q4	$1.78M	Hold	1,536	–	–	0.02%	590
2018 Q3	$2.33M	Buy	1,536 +1,431	+1,363%	+$2.2M	0.02%	573
2018 Q2	$164K	Buy	105 +1	+1%	+$1.3K	﹤0.01%	1268
2018 Q1	$120K	Hold	104	–	–	﹤0.01%	1337
2017 Q4	$123K	Hold	104	–	–	﹤0.01%	1353
2017 Q3	$140K	Hold	104	–	–	﹤0.01%	1350
2017 Q2	$84K	Buy	+104	New	+$72.4K	﹤0.01%	1416
2016 Q1	–	Hold	0	–	-$1K	–	2008
2015 Q4	–	Hold	0	–	–	–	1629

Other funds holding KYNB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

QS Investors's KYNB Position: Q2 2021 in Review

QS Investors held its Kyntra Bio (KYNB) position steady in Q2 2021 at 384 shares worth $256K. The position accounts for ﹤0.01% of the portfolio, ranked #991.

QS Investors first reported a position in KYNB in Q2 2017 and has held it in 17 quarters since. The position peaked at $2.33M in Q3 2018. 174 funds tracked by Wall St. Rank hold KYNB as of Q2 2021.

QS Investors held 384 shares of Kyntra Bio worth $256K as of Q2 2021.
QS Investors left its Kyntra Bio share count unchanged in Q2 2021.
Kyntra Bio made up ﹤0.01% of QS Investors's portfolio in Q2 2021, its #991 holding.
QS Investors first reported a position in Kyntra Bio in Q2 2017 and has held it in 17 quarters since.
QS Investors's Kyntra Bio position peaked at $2.33M in Q3 2018.
174 funds tracked by Wall St. Rank held Kyntra Bio as of Q2 2021.

Based on QS Investors's 13F filing for Q2 2021, filed 13 Aug 2021.